Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Tax Provisions (2017 - 2025)

Lisata Therapeutics filings provide 11 years of Tax Provisions readings, the most recent being -$962000.0 for Q1 2025.

  • For the quarter ending Q1 2025, Tax Provisions fell 20.55% year-over-year to -$962000.0, compared with a TTM value of -$962000.0 through Dec 2025, down 20.55%, and an annual FY2025 reading of -$962000.0, down 20.55% over the prior year.
  • Tax Provisions hit -$962000.0 in Q1 2025 for Lisata Therapeutics, down from -$798000.0 in the prior quarter.
  • The five-year high for Tax Provisions was -$798000.0 in Q1 2024, with the low at -$2.3 million in Q2 2023.
  • Median Tax Provisions over the past 3 years was -$962000.0 (2025), compared with a mean of -$1.4 million.
  • The largest YoY upside for Tax Provisions was 20.55% in 2025 against a maximum downside of 20.55% in 2025.
  • Year by year, Tax Provisions stood at -$2.3 million in 2023, then skyrocketed by 65.75% to -$798000.0 in 2024, then fell by 20.55% to -$962000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$962000.0, -$798000.0, and -$2.3 million for Q1 2025, Q1 2024, and Q2 2023 respectively.